Use of advanced systemic therapy in adolescent patients with moderate-to-severe atopic dermatitis in the TARGET-DERM Registry

Main Article Content

Michael Haft
Keith Knapp
Ami Claxton
Breda Munoz
Sanjeev Balu
Shannon Schnieder
Jonathan Silverberg
Diamant Thaci
Lawrence Eichenfield


Atopic Dermatitis, Registry, Target RWE, Advanced Systemic Therapy, vIGA-AD, Treatment, Naive, POEM, BSA


1. Nutten, S., Atopic dermatitis: global epidemiology and risk factors. Ann Nutr Metab, 2015. 66 Suppl 1: p. 8-16.

2. AD Langan SM, Irvine AD, Weidinger S. Lancet. 2020 Aug 1;396(10247):345-360.

3. Abuabara, K. International observational atopic dermatitis cohort to follow natural history and treatment course: TARGETDERM AD study design and rational BMJ Open 2020;10:e0399282020.

Similar Articles

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)

1 2 3 4 5 6 > >>